Robert E. Conway - 15 Dec 2022 Form 4 Insider Report for ARCA biopharma, Inc. (ORKA)

Reporting owner
Role
Director, Chairman of the Board
Signature
/s/ C. Jeffrey Dekker, Attorney-in-Fact
Issuer context
Issuer symbol
ORKA
Transaction snapshot
Transactions as of
15 Dec 2022
Net transaction value
$0
SEC evidence
Form type
4
Filing time
19 Dec 2022, 15:20:06 UTC
Previous filing
04 Jan 2022
Next filing
05 Jan 2023
SEC filing
View on sec.gov

Key filing fact

Robert E. Conway filed Form 4 for ARCA biopharma, Inc. (ORKA) on 19 Dec 2022.

Key facts

  • This page summarizes Robert E. Conway's Form 4 filing for ARCA biopharma, Inc. (ORKA).
  • 1 reported transaction and 1 derivative row are listed below.
  • Filing timestamp: 19 Dec 2022, 15:20.

Change

  • Previous filing in this sequence was filed on 04 Jan 2022.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reported transactions

ABIO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
50,000
Date
15 Dec 2022
Ownership
Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

ABIO transaction Derivative

Stock Option (right to buy)

Award

Transaction value
$0
Shares
+6,000
Change %
Price
$0.000000
Shares after
6,000
Date
15 Dec 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
6,000
Exercise price
$2.32
Footnotes
F1
* indicates a reported price that failed the local validity check.

Explanation of Responses:

Id Content
F1 Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of December 15, 2022. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .